semaglutide comes from There's still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming New obesity drug semaglutide is

Clinically, qualifying for GLP-1 therapy typically requires meeting one of two conditions: a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater combined with an obesity-related comorbidity such as type 2 diabetes or cardiovascular risk factors

Severe symptoms like sudden stomach pain, yellow eyes, or trouble breathing need medical help right away

By enhancing insulin production and reducing glucose release from the liver, Ozempic is designed to control blood sugar and aid weight loss in diabetic patients

AMX0035 is in its Phase 2 HELIOS trial, and Amylyx has already delivered positive results at both the Week 24 and Week 48 milestones